Fig. 4From: Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorderChanges from baseline to the end of treatment in ADHD RS-IV-J:I score for TS-141 (FAS). A subgroup analysis evaluated the efficacy between the dose and CYP2D6 phenotype. To compare the change for each CYP2D6 under the constant dose, lines were drawn at each doseBack to article page